Norway Glp-1 Receptor Agonist Market Size & Outlook

Name: Norway Glp-1 Receptor Agonist Market Size & Outlook
Creator: Grand View Research
License: https://www.grandviewresearch.com/horizon/info/terms-of-use

The glp-1 receptor agonist market in Norway is expected to reach a projected revenue of US$ 714.3 million by 2033. A compound annual growth rate of 7.9% is expected of Norway glp-1 receptor agonist market from 2026 to 2033.

Norway glp-1 receptor agonist product outlook (Revenue, USD million, 2021-2033)
- Semaglutide (Ozempic, Wegovy, Rybelsus)
- Tirzepatide (Mounjaro, Zepbound)
- Dulaglutide (Trulicity)
- Liraglutide (Victoza, Saxenda)
- Others (Byetta, Bydureon, SOLIQUA)
Norway glp-1 receptor agonist application outlook (Revenue, USD million, 2021-2033)
- Type 2 Diabetes Mellitus
- Obesity / Chronic Weight Management
- Cardiovascular Risk
Norway glp-1 receptor agonist route of administration outlook (Revenue, USD million, 2021-2033)
- Injectable / Parenteral
- Oral
Norway glp-1 receptor agonist distribution channel outlook (Revenue, USD million, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies

Norway Glp-1 Receptor Agonist Market Size & Outlook

Sign up - it's easy, and free!